Carisma Therapeutics Inc.: directors' dealings · United States · SEC (Form 4)

About Carisma Therapeutics Inc.

Carisma Therapeutics Inc. is a U.S.-listed biotechnology company whose common stock has been associated with the NASDAQ market, and it is headquartered in Philadelphia, Pennsylvania, United States. The company was founded in 2016 around a differentiated scientific thesis: engineering macrophages, key cells of the innate and adaptive immune system, into a proprietary cell-therapy platform. Michael Klichinsky co-founded the company and now serves as Chief Scientific Officer, while Steven Kelly has led Carisma as President and Chief Executive Officer since 2018. That leadership profile underscores the company’s strong research-to-development orientation. ([ir.carismatx.com](https://ir.carismatx.com/)) Carisma’s core business is built on its proprietary engineered-macrophage platform, initially developed in collaboration with the University of Pennsylvania. The first applications of the platform were autologous CAR-macrophages for solid tumors, a highly challenging oncology setting where conventional CAR-T approaches often face biological constraints such as the solid-tumor microenvironment, antigen heterogeneity, and trafficking limitations. More recently, the company has also highlighted programs in liver fibrosis and additional precision-medicine opportunities, making it more of a platform developer than a single-asset biotech. ([ir.carismatx.com](https://ir.carismatx.com/)) From a competitive standpoint, Carisma operates in a narrow but potentially transformative segment of next-generation cell therapy. Its main differentiator is macrophage engineering, which aims to address some of the intrinsic weaknesses of T-cell-based therapies in solid tumors. As a result, Carisma is not a scale player in commercial pharma terms; instead, it is a high-science, high-risk platform company whose value creation depends on preclinical validation, clinical execution, and the ability to secure strategic partnerships or other forms of capital. ([ir.carismatx.com](https://ir.carismatx.com/)) Recent company updates are material. In March 2025, Carisma announced a strategic review and revised operating plan, stating its intention to maximize the value of its oncology and liver-fibrosis programs as well as its macrophage and monocyte engineering platforms. The company also disclosed preclinical data for an anti-GPC3 in vivo CAR-M therapy in hepatocellular carcinoma and described CT-1119 as a next-generation CAR-monocyte for mesothelin-positive solid tumors, including pancreatic, ovarian, lung cancer and mesothelioma. In addition, Carisma announced the delisting of its common stock from Nasdaq and a plan to file Form 15 to suspend SEC reporting, which is an important development for investors following the stock. In practical terms, Carisma remains a speculative U.S. biotech story, with valuation driven primarily by scientific milestones, balance-sheet preservation, and the monetization potential of its platform and pipeline. ([ir.carismatx.com](https://ir.carismatx.com/news-releases/news-release-details/carisma-therapeutics-provides-corporate-updates?utm_source=openai))